Prevalence and clinical significance of autoantibodies in adults with cystic fibrosis

European Respiratory Journal

Volumn 34, Issue 5, 2009, Pages 1079-1085

  Lachenal, F ^a,d   Nkana, K ^a,d   Nove Josserand, R ^a,d   Fabien, N ^a,b,c,d   Durieu, I ^a,b,d  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c INSERM   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Antineutrophil cytoplasmic antibodies; Autoimmune diseases; Bactericidal permeability increasing protein; Cystic fibrosis; Inflammation; Pseudomonas aeruginosa

Indexed keywords

AUTOANTIBODY; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; IMMUNOGLOBULIN A ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNITY; BACTERIAL COLONIZATION; BODY MASS; CHRONIC RESPIRATORY FAILURE; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GENDER; HUMAN; HYPERGAMMAGLOBULINEMIA; INFLAMMATION; LUNG DISEASE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIBODIES; COHORT STUDIES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN A; MALE; PREVALENCE; RETROSPECTIVE STUDIES; SACCHAROMYCES CEREVISIAE;

EID: 71049125383     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00006009     Document Type: Article

References (32)

1. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-1191.
2. Elborn JS. How can we prevent multisystem complications of cystic fibrosis? Semin Respir Crit Care Med 2007; 28: 303-311.
3. Dorlochter L, Carlsson M, Olafsdottir EJ, et al. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis. J Cyst Fibros 2004; 3: 179-183. (Pubitemid 39194073)
4. Carlsson M, Eriksson L, Pressler T, et al. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis. J Cyst Fibros 2007; 6: 228-233. (Pubitemid 46567795)
5. Berlie I, Leboucher B, Leblanc M, et al. Anticorps anticytoplame des polynucléaires neutrophiles au cours de la mucoviscidose. Fréquence et signification [Antineutrophil cytoplasmic antibodies in cystic fibrosis. Frequency and significance]. Arch Pediatr 2005; 12: 140-143.
6. Schultz H. From infection to autoimmunity: a new model for induction of ANCA against the bactericidal/permeability increasing protein (BPI). Autoimmun Rev 2007; 6: 223-227. (Pubitemid 46274546)
7. Carmona E, Perez-Aguilar F, Lopez JA, et al. Anti-neutrophil-cytoplasmic auto-antibodies (ANCA) in 105 patients (56 adults and 49 children) suffering from cystic fibrosis, attending a Spanish hospital. J Intern Med 2002; 252: 281-282.
8. Condino AA, Hoffenberg EJ, Accurso F, et al. Frequency of ASCA seropositivity in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 41: 23-26. (Pubitemid 40967350)
9. Coffey M, Hassan J, Feighery C, et al. Rheumatoid factors in cystic fibrosis: associations with disease manifestations and recurrent bacterial infections. Clin Exp Immunol 1989; 77: 52-57. (Pubitemid 19198812)
10. Hassan J, Feighery C, Bresnihan B, et al. Prevalence of anti-Fab antibodies in patients with autoimmune and infectious diseases. Clin Exp Immunol 1992; 89: 423-426.
11. Stechova K, Kolouskova S, Sumnik Z, et al. Anti-GAD65 reactive peripheral blood mononuclear cells in the pathogenesis of cystic fibrosis related diabetes mellitus. Autoimmunity 2005; 38: 319-323. (Pubitemid 40974961)
12. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998; 132: 589-595.
13. Garner JS, Jarvis WR, Emori TG, et al. CDC definition for nosocomial infections. In: Olmstead RN, ed. Infection Control and Applied Epidemiology: Principles and Practice. Mosby, St. Louis, 1996.
14. Elsbach P, Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol 1998; 10: 45-49. (Pubitemid 28112078)
15. Zhao MH, Jayne DR, Ardiles LG, et al. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM 1996; 89: 259-265. (Pubitemid 3041699)
16. Schinke S, Fellermann K, Herlyn K, et al. Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability- increasing protein. Inflamm Bowel Dis 2004; 10: 763-770. (Pubitemid 39545222)
17. Aichele D, Schnare M, Saake M, et al. Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients. Infect Immun 2006; 74: 4708-4714. (Pubitemid 44157258)
18. Mahadeva R, Dunn AC, Westerbeek RC, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease. Clin Exp Immunol 1999; 117: 561-567. (Pubitemid 29398306)
19. Hoffenberg EJ, Fidanza S, Sauaia A. Serologic testing for inflammatory bowel disease. J Pediatr 1999; 134: 447-452. (Pubitemid 30180626)
20. Lloyd-Still JD. Crohn's disease and cystic fibrosis. Dig Dis Sci 1994; 39: 880-885.
21. Botton E, Saraux A, Laselve H, et al. Musculoskeletal manifestations in cystic fibrosis. Joint Bone Spine 2003; 70: 327-335.
22. Rush PJ, Shore A, Coblentz C, et al. The musculoskeletal manifestations of cystic fibrosis. Semin Arthritis Rheum 1986; 15: 213-225.
23. Doyen V, Fournier C, Bautin N, et al. Polyarthrite rhumatoïde et mucoviscidose [Rheumatoid arthritis and cystic fibrosis]. Rev Mal Respir 2005; 22: 667-671. (Pubitemid 40627050)
24. Minicucci L, Cotellessa M, Pittaluga L, et al. Beta-cell autoantibodies and diabetes mellitus family history in cystic fibrosis. J Pediatr Endocrinol Metab 2005; 18: 755-760. (Pubitemid 41309338)
25. Costa M, Potvin S, Berthiaume Y, et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab 2005; 31: 221-232. (Pubitemid 40961519)
26. Wilschanski M, Durie PR. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut 2007; 56: 1153-1163. (Pubitemid 47123248)
27. Durieu I, Pellet O, Simonot L, et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol 1999; 30: 1052-1056. (Pubitemid 29278749)
28. Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis. Chest 2008; 133: 489-495.
29. Balfour-Lynn IM. Anti-inflammatory approaches to cystic fibrosis airways disease. Curr Opin Pulm Med 2007; 13: 522-528. (Pubitemid 47494202)
30. Eigen H, Rosenstein BJ, Fitzsimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995; 126: 515-523.
31. Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest 2008; 118: 1040-1049.
32. Buranawuti K, Boyle MP, Cheng S, et al. Variants in mannose-binding lectin and tumour necrosis factor-α affect survival in cystic fibrosis. J Med Genet 2007; 44: 209-214. (Pubitemid 46580531)